<DOC>
	<DOCNO>NCT00302224</DOCNO>
	<brief_summary>The study design test safety , tolerability newly develop form ketoconazole ( DIO-902 ) treatment elevate blood sugar type 2 diabetes . This study also also examine effect drug total LDL cholesterol blood pressure . Elevated cortisol may contribute development Type II diabetes . The investigational drug DIO-902 may reduce level cortisol blood therefore provide good control blood sugar level patient Type II diabetes .</brief_summary>
	<brief_title>A Phase 1/2a Study 2S,4R Enantiomer Ketoconazole Subjects With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>DiObex develop modified form ketoconazole ( enantiomer ) ( DIO-902 ) investigational new drug treatment elevate blood sugar associate type 2 diabetes . Other benefit may include reduced total LDL cholesterol , reduce blood pressure . With chronic treatment , reduce visceral fat may also see . Ketoconazole ( racemic ) approve drug treatment variety fungal infection . The approved racemic ketoconazole inhibits cortisol synthesis . In patient Cushings Disease racemic ketoconazole reduces glucose , cholesterol blood pressure . Elevated cortisol may contribute causal factor development type 2 diabetes ; clinical trial racemic ketoconazole carry patient . The result clinical trial support concept treat type 2 diabetes lower plasma cortisol provide evidence safety tolerability racemic ketoconazole . Racemic ketoconazole , however , associate liver toxicity generally mild nature . However , rare case ( 1:10,000 15,000 patient ) severe liver toxicity may occur , extremely rare case adverse event may irreversible life-threatening . Preclinical result suggest DIO-902 may safer efficacious racemic mixture .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Ketoconazole</mesh_term>
	<criteria>1 . Male female , age 18 70 2 . Females nonlactating use adequate contraception , opinion Principal Investigator negative serum pregnancy test child bear potential ( intact uterus premenopausal ) 3 . Diagnosis type 2 diabetes mellitus ( DM ) least 6 month . Type 2 diabetes may untreated may treat diet exercise and/or pharmacologic therapy Inclusion Criterion 4 4 . Pharmacologic treatment type 2 DM may include follow must stable &gt; 3 month Glucophage ( Metformin ) ( &lt; maximum dose 2550 mg ) Glucophage XR ( &lt; maximum dose 2000 mg ) 5 . HbA1C level 6.5 10.9 % 6 . Fasting Cpeptide level great equal 0.8 nmol/L ( 2.4 ng/mL ) 7 . ACTH stimulation test result cortisol level ( baseline , 30 60 minute ) &gt; 18 µg/dL 8 . Normal thyroid stimulate hormone 9.12lead electrocardiogram ( ECG ) show acute ischemia clinically significant abnormality 10.BMI 26 40 kg/m2 11.Subjects history hypertension may stable antihypertensive regimen ( except drug state Exclusion Criterion 7 ) &gt; 2 month 12.Ability comprehend willingness provide inform consent 1 . History atherosclerotic disorder ( myocardial infarction , angina , cerebrovascular accident , peripheral vascular disease congestive heart failure secondary ischemic myocardial injury ) would , estimation Investigator , make unsafe stop lipid lower drug course study 2 . Known hypersensitivity idiosyncratic reaction relate ketoconazole imidazole compound 3 . History malignancy ( except basal cell carcinoma ) within 3 year initial dose study medication 4 . Excessive alcohol intake drug abuse use Diagnostic Statistical Manual Mental Disorders , 4th edition ( DSM IV ) , criterion 5 . Any clinically significant medical condition , determine Investigator . These clinically significant medical condition include proliferative diabetic retinopathy neuropathic symptom limit activity daily live 6 . Participation another clinical trial and/or treatment receive investigational agent within one month initial dose study medication 7 . Concomitant therapy following : antacid ulcer medication , weight loss medication , oral inject hypoglycemics ( metformin allow ) insulin , steroid , cyclosporine , tacrolimus , midazolam , digoxin , coumarin derivative , phenytoin , rifampin , loratadine , HIV protease inhibitor , spironolactone , thiazide diuretic , calcium channel blocker erythromycin . Subjects take lipid lower medication may enrol Investigator determines subject condition preclude cessation subject willing stop medication 21 day prior Study Visit 1 Study Visit 3 ( Day 16 ) 8 . History HIV 9 . Positive hepatitis B ( HBsAg ) positive hepatitis C ( Hepatitis C antibody ) test Screening 10 . WBC count &lt; 4000/µL &gt; 14,000/µL 11 . Hemoglobin &lt; 12.0 gm/dL female &lt; 14.0 gm/dL male 12 . Any single hepatic enzyme ( ALT , AST , AP total bilirubin ) great upper limit normal reference range use central laboratory 13 . Creatinine &gt; 1.5 time upper limit normal 14 . Known hypersensitivity cosyntropin ( ACTH ) component formulation ( mannitol sodium chloride )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2008</verification_date>
	<keyword>safety</keyword>
	<keyword>type 2 diabetes</keyword>
</DOC>